# Alessandro Armuzzi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alessandro-armuzzi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,831 |
| Field | Inflammatory Bowel Disease |
| h-index | 72 |
| i10-index | 299 |
| Last Known Institution | Humanitas University |
| OpenAlex ID | https://openalex.org/A5058934291 |
| ORCID iD | https://orcid.org/0000-0003-1572-0118 |
| Works | 937 |

## Researcher papers

- [Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders](https://scholariq.org/papers/third-european-evidence-based-consensus-on-diagnosis-and-management-of/)
- [ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-medical-treatment/)
- [ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment](https://scholariq.org/papers/ecco-guidelines-on-therapeutics-in-crohn-s-disease-surgical-treatment/)
- [Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn’s Disease](https://scholariq.org/papers/mongersen-an-oral-i-smad7-i-antisense-oligonucleotide-and-crohn-s-disease/)
- [Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease](https://scholariq.org/papers/advanced-age-is-an-independent-risk-factor-for-severe-infections-and-mortality/)
- [Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study](https://scholariq.org/papers/effect-of-different-probiotic-preparations-on-anti-helicobacter-pylori-therapy/)
- [Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study](https://scholariq.org/papers/outcomes-of-covid-19-in-79-patients-with-ibd-in-italy-an-ig-ibd-study/)
- [Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial](https://scholariq.org/papers/ustekinumab-versus-adalimumab-for-induction-and-maintenance-therapy-in-biologic/)
- [Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease](https://scholariq.org/papers/deep-remission-at-1-year-prevents-progression-of-early-crohn-s-disease/)
- [The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆](https://scholariq.org/papers/the-italian-society-of-gastroenterology-sige-and-the-italian-group-for-the-study/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)
- [Helicobacter pylori-related gastroenterology studies](https://scholariq.org/topics/helicobacter-pylori-related-gastroenterology-studies/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Researcher university

- [Humanitas University](https://scholariq.org/institutions/humanitas-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.